RUNX2 and prostate carcinoma: Another review described that silybin (A+B) inhibits osteoclast activity and differentiation induced by metastatic prostate cancer cells in RAW264.7 cells by decreasing the DNA binding activity of NFATc1 and its regulators NF-κB and AP1, induced by RANKL, osteoclast-specific markers (cathepsin K, OSCAR, and TRAP), and osteomimicry biomarkers (OC, RANKL, PTHrP, and Runx2) in cell culture (PC3 and C4-2B cells), and helps diagnose PC3 tumors (Mia et al., 2023).